NYSE:ZYME

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Zymeworks's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ZYME's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.0%

ZYME

-1.5%

US Biotechs

3.8%

US Market


1 Year Return

74.9%

ZYME

22.1%

US Biotechs

9.7%

US Market

Return vs Industry: ZYME exceeded the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: ZYME exceeded the US Market which returned 9.7% over the past year.


Shareholder returns

ZYMEIndustryMarket
7 Day-4.0%-1.5%3.8%
30 Day-4.4%3.5%11.4%
90 Day-4.0%9.0%6.8%
1 Year74.9%74.9%23.3%22.1%12.1%9.7%
3 Year290.2%290.2%26.1%22.1%36.2%27.2%
5 Yearn/a-5.5%-11.0%63.7%45.4%

Price Volatility Vs. Market

How volatile is Zymeworks's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zymeworks undervalued compared to its fair value and its price relative to the market?

3.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ZYME's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZYME is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ZYME is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZYME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZYME is good value based on its PB Ratio (3.2x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Zymeworks forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-0.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYME's revenue (50% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: ZYME's revenue (50% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZYME is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Zymeworks performed over the past 5 years?

-43.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ZYME is currently unprofitable.

Growing Profit Margin: ZYME is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZYME is unprofitable, and losses have increased over the past 5 years at a rate of -43% per year.

Accelerating Growth: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ZYME has a negative Return on Equity (-31.19%), as it is currently unprofitable.


Next Steps

Financial Health

How is Zymeworks's financial position?


Financial Position Analysis

Short Term Liabilities: ZYME's short term assets ($504.6M) exceed its short term liabilities ($72.9M).

Long Term Liabilities: ZYME's short term assets ($504.6M) exceed its long term liabilities ($41.3M).


Debt to Equity History and Analysis

Debt Level: ZYME is debt free.

Reducing Debt: ZYME had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZYME has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ZYME has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 10.5% each year


Next Steps

Dividend

What is Zymeworks's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZYME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZYME's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ali Tehrani (47yo)

no data

Tenure

US$3,278,069

Compensation

Dr. Ali Tehrani, Ph.D. is a Co-Founder of Zymeworks, Inc. and serves as its Chief Executive Officer and President. Dr. Tehrani has been an integral part of many of Zymeworks' corporate achievements, includ ...


CEO Compensation Analysis

Compensation vs Market: Ali's total compensation ($USD3.28M) is below average for companies of similar size in the US market ($USD4.76M).

Compensation vs Earnings: Ali's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ali Tehrani
Co-Founderno dataUS$3.28m0.70% $11.6m
Anthony Polverino
Chief Scientific Officer & Executive VP of Early Development1.75yrsUS$1.34m0.064% $1.1m
Kathryn O'Driscoll
Chief People Officer0.67yrUS$2.39mno data
Diana Hausman
Chief Medical Officer4yrsUS$1.40m0.012% $195.8k
Neil Klompas
Executive VP of Business Operations & CFOno dataUS$1.05m0.021% $349.0k
Surjit Dixit
Vice President of Technologyno dataUS$497.90kno data
Daniel Dex
VP of Legal & Corporate Secretaryno datano datano data
John Babcook
Senior Vice President of Discovery Research4.25yrsUS$400.71kno data
Mark Hollywood
Senior Vice President of Technical & Manufacturing Operations1.25yrsno datano data
James Daniel Priour
Senior Vice President of Commercialno datano datano data

1.8yrs

Average Tenure

52.5yo

Average Age

Experienced Management: ZYME's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ali Tehrani
Co-Founderno dataUS$3.28m0.70% $11.6m
Hollings Renton
Independent Director3.33yrsUS$172.16kno data
Lota Zoth
Independent Chair of the Board of Directors0.75yrUS$184.19kno data
Kenneth Hillan
Independent Director3.33yrsUS$107.79kno data
Kelvin Neu
Independent Director0.25yrno datano data
Susan Mahony
Independent Director1yrUS$392.85kno data
Natalie Sacks
Independent Director2.83yrsUS$160.61kno data
Troy Cox
Independent Director1yrUS$392.48k0.016% $274.5k

1.9yrs

Average Tenure

55yo

Average Age

Experienced Board: ZYME's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ZYME insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.1%.


Top Shareholders

Company Information

Zymeworks Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zymeworks Inc.
  • Ticker: ZYME
  • Exchange: NYSE
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.667b
  • Shares outstanding: 45.54m
  • Website: https://www.zymeworks.com

Number of Employees


Location

  • Zymeworks Inc.
  • 1385 West 8th Avenue
  • Suite 540
  • Vancouver
  • British Columbia
  • V6H 3V9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZYMENYSE (New York Stock Exchange)YesCommon SharesUSUSDApr 2017
ZYMETSX (The Toronto Stock Exchange)YesCommon SharesCACADApr 2017
0OXDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2017

Biography

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and collaboration with Applied BioMath, LLC. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 06:12
End of Day Share Price2020/06/05 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.